WallStSmart
NRIX

Nurix Therapeutics Inc

NASDAQ: NRIX · HEALTHCARE · BIOTECHNOLOGY

$16.61
-2.75% today

Updated 2026-04-29

Market cap
$1.72B
P/E ratio
P/S ratio
23.93x
EPS (TTM)
$-3.17
Dividend yield
52W range
$8 – $23
Volume
1.1M

Nurix Therapeutics Inc (NRIX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$37.45M$31.11M$17.82M$29.75M$38.63M$76.99M$54.55M$83.98M
Revenue growth (YoY)-16.9%-42.7%+66.9%+29.8%+99.3%-29.1%+54.0%
Cost of revenue$40.51M$45.02M$66.49M$6.08M$10.81M$189.15M$221.63M$18.86M
Gross profit$-3.06M$-13.91M$17.82M$29.75M$38.63M$-112.16M$-167.08M$65.12M
Gross margin-8.2%-44.7%100.0%100.0%100.0%-145.7%-306.3%77.5%
R&D$40.51M$45.02M$66.49M$116.43M$184.50M$189.15M$221.63M$308.16M
SG&A$6.67M$8.33M$16.31M$31.20M$38.00M$42.90M$45.94M$52.74M
Operating income$-9.74M$-22.24M$-64.98M$-117.89M$-183.87M$-155.06M$-213.03M$-285.67M
Operating margin-26.0%-71.5%-364.7%-396.3%-476.0%-201.4%-390.5%-340.2%
EBITDA$-6.75M$-19.88M$-62.80M$-111.80M$-173.06M$-148.93M$-205.01M$-244.84M
EBITDA margin-18.0%-63.9%-352.4%-375.8%-448.0%-193.4%-375.8%-291.5%
EBIT$-9.74M$-22.24M$-64.98M$-117.89M$-183.87M$-155.06M$-213.03M$-263.70M
Interest expense$818000.00$776000.00$3.39M$6.91M$14.31M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-9.43M$-21.70M$-43.24M$-117.19M$-166.04M$-143.95M$-193.57M$-264.46M
Net income growth (YoY)-130.2%-99.3%-171.0%-41.7%+13.3%-34.5%-36.6%
Profit margin-25.2%-69.7%-242.7%-393.9%-429.9%-187.0%-354.9%-314.9%